BioMarin PharmaceuticalsBMRN
BMRN
About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Employees: 3,040
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 55
39% more repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 171
11% more call options, than puts
Call options by funds: $97.7M | Put options by funds: $87.7M
7% more funds holding
Funds holding: 534 [Q4 2024] → 573 (+39) [Q1 2025]
6% more capital invested
Capital invested by funds: $12B [Q4 2024] → $12.8B (+$743M) [Q1 2025]
0.65% less ownership
Funds ownership: 96.11% [Q4 2024] → 95.46% (-0.65%) [Q1 2025]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$78
39%
upside
Avg. target
$91
62%
upside
High target
$104
85%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Goldman Sachs Salveen Richter | 85%upside $104 | Buy Maintained | 5 May 2025 |
Citigroup David Lebovitz | 39%upside $78 | Neutral Maintained | 2 May 2025 |
Financial journalist opinion
Based on 8 articles about BMRN published over the past 30 days
Positive
The Motley Fool
1 week ago
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Positive
Finbold
2 weeks ago
2 top value stocks to buy for second half of 2025
The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
Neutral
Zacks Investment Research
2 weeks ago
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
Positive
Zacks Investment Research
2 weeks ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
Business Wire
3 weeks ago
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of Inozyme that they own. KSF is seeking to determine whether this consideration and the process that.
Positive
Zacks Investment Research
3 weeks ago
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Positive
Investors Business Daily
4 weeks ago
How BioMarin's $270 Million Takeover Led This Dollar Stock To A Triple-Digit Gain
BioMarin said Friday it would spend $270 million to acquire Inozyme Pharma, sending shares of the latter skyrocketing by triple digits.
Neutral
PRNewsWire
4 weeks ago
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif.
Neutral
PRNewsWire
1 month ago
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif. , May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO ® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions.
Positive
Zacks Investment Research
1 month ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™